Lorna has enjoyed a successful 25-year career in the pharmaceutical industry, encompassing clinical research, business development, marketing, and sales across a wide variety of therapeutic areas, including respiratory, CNS, cardiopulmonary, oncology, metabolic, psychiatry, neurology, HIV, pain, and vaccines. She has worked in the United States, Europe, and the Asia Pacific. She immigrated to Australia in 2002 and worked for GSK Australia as the Commercial Vice President for 5 years. In 2009, she established Ikaria Australia Ltd Pty., a biotherapeutics company that commercialised drugs and devices for intensive care medicine. Lorna is currently Vice President, Commercial Operations, Asia Pacific of Seqirus bioCSL Ltd. (A CSL company). She served on the Board of BioMelbourne Network (an industry-led membership association for organisations engaged in biotechnology, medical technology, and health innovation in the state of Victoria) for 8 years, including holding the position of Secretary. Lorna graduated with a PhD in Neurobiology (University College London) and a BSc in Pharmacology (University of Glasgow), and went on to hold academic positions at the Cardiothoracic Institute at the Royal Brompton Hospital (London) and the Royal Post Graduate Medical School (London).
Mark was previously a clinical programme head at GSK in London, Associate Director, Clinical at Gilead Sciences in California, and Chief Operating Officer of Australia’s vaccine design and development consortium at the University of New South Wales. He has contributed to three successful global registrational programs for HIV and hepatitis B therapeutics, has worked on 40 small molecule and biologic development programs at all stages, and led the development of moxidectin through FDA approval. Mark is the 2019 Victorian Australian of the Year.
Andrew Wilks, BSc, PhD, was most recently Chief Scientific Officer and founder of Cytopia. Prior to starting Cytopia, Andrew was at the Ludwig Institute for Cancer Research in Melbourne where he discovered the JAK kinases. He holds an Honorary Professorship at Monash University (Melbourne) and was the inaugural winner of the Australian Biobusiness Award in 2007. Based in Melbourne, Australia, Andrew co-founded SYN|thesis in 2007 and now oversees global operations.
Richard has over 25 years’ experience in negotiating and documenting commercial arrangements and is highly regarded for his expertise in advising clients on all aspects of commercial transactions and corporate issues. Richard was a founding partner of the Banki Haddock Fiora partnership in 1995. His clients include research organisations and universities, statutory corporations, educators, primary industry bodies, publishers, and media operators.
Amanda serves as senior director overseeing the development of a low-cost neonatal vaccine for rotavirus and also contributing to new collaboration assessment of vaccines, global project development, funding opportunity assessments, and collaborative networks. Prior to joining MDGH in 2005, Amanda was a Senior Scientist and Manager of Clinical Analysis within research and development at Bavarian Nordic GmbH, living in Denmark and Germany. Amanda has gained extensive experience in product development teams in research, preclinical, and clinical for smallpox, HIV, and other viral vector vaccines. Amanda holds a first-class Honours degree in Biological Sciences and a Master’s of Public Health in Epidemiology from the University of Melbourne. When not making medicines for those that need them most, Amanda is out and about with her family, knitting beanies for babies, and learning Danish.
Danielle is an associate director overseeing regulatory affairs operations and contributing to directional strategy, including global drug access and new collaboration, development, and funding opportunity assessments. Prior to joining MDGH in 2008, Danielle was an Australian Research Council/Center of Excellence Research Fellow and lecturer at Monash University, Australia, with a small group of staff and post-graduate students and a broad collaborative network studying host-pathogen immunology and the biochemistry of cell death in health and disease. Danielle is a graduate of Monash University and has a PhD in immunology from the University of Melbourne. Danielle has been fascinated by immunology since she first learned about the weaponry pathogens deploy on their human hosts. When not working for global health equity, she is most likely to be found in a Melbourne coffee shop or at a park with her husband and their wolfhound.
John serves as senior director, primarily supporting the manufacture and supply of moxidectin tablets but also helping manage MDGH’s non-clinical development activities. Prior to joining MDGH in 2016, John served as Vice President, Drug Development and Director, Drug Discovery at Biota Pharmaceuticals where he worked on respiratory antiviral drugs and nucleosides intended for the treatment of hepatitis C. While at Biota, John was fortunate to be able to work across the drug discovery and development lifecycle. Before making the move to industry in 2002, John was a Senior Lecturer at the University of Melbourne, an ARC QEII Fellow at the Australian National University, and a post-doctoral fellow at Harvard University. John holds a PhD in synthetic organic chemistry from the University of Melbourne and is a graduate of the Australian Institute of Company Directors. He lives in Melbourne with his wife, children, and dog. When not diving into the vagaries of drug product manufacture and control, John enjoys cycling, pretending to surf, and all-grain brewing.
Larry joined Medicines Development in 2012 as a highly experienced biotechnology executive with broad R&D, product development, operational, and general management experience, including manufacturing, preclinical and clinical development, and regulatory affairs. He has direct experience in the development of therapeutic vaccines for HIV, HBV, and cancer targets. He has more than 14 years experience in the biotechnology industry at companies including AMRAD and Virax in positions spanning from Laboratory Director to CEO. Larry’s medical research experience is drawn from more than 10 years as a senior medical researcher in leading Australian and international institutes.